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introduction
Myelodysplastic syndromes (MDS) are clonal haematopoietic
stem cell (HSC) disorders predominating in the elderly, charac-
terised by ineffective haematopoiesis leading to blood cytopaenias
and by progression to acute myeloid leukaemia (AML) in one-
third of cases [1]. Their pathophysiology is a multistep process
involving cytogenetic changes and/or gene mutations [2] and
widespread gene hypermethylation at advanced stages [3–5].
Diagnosis of MDS is based on the blood and marrow examin-
ation, showing blood cytopaenias, hypercellular marrow with
dysplasia, with or without an excess of immature marrow cells
(blasts) [6]. Prognosis is largely based on the marrow blast
percentage, number and extent of cytopaenias and cytogenetic ab-
normalities, which are grouped in a recently Revised International
Prognostic Scoring system (IPSS/IPSS-R) [7, 8]. Treatment
varying from symptomatic therapy of cytopaenias, especially by
transfusions, to allogeneic stem cell transplantation (alloSCT)
has improved in the last few years.
incidence and aetiology
MDS are diseases of the elderly, with a median age at diagnosis
of ∼70 years and with >10% of the patients being younger than
50 years of age [9]. The incidence of MDS in Europe is about 4
cases/100 000 inhabitants/year (reaching 40–50/100 000 in
patients aged ≥70 years) [9]. There are no known ethnic differ-
ences in the incidence of MDS, but MDS in Asian populations
tend to occur at an earlier age, more often have a hypocellular
marrow and present less often with isolated 5q deletion (5q-
syndrome), while trisomy 8 seems to be more frequent than in
Western populations [10, 11].
The aetiology of MDS is known in only 15% of cases. Inherited
predisposition to MDS is seen in one-third of paediatric MDS
cases, including in Down’s syndrome, Fanconi anaemia and neu-
rofibromatosis. It is less frequent in adults, where an inherited
predisposition should also be assessed in MDS occurring in
young adults or in families with other cases of MDS, AML or aplas-
tic anaemia. Environmental factors include previous use of chemo-
therapy, especially alkylating agents and more recently of purine
analogues [12] radiotherapy or ionising radiation [13, 14], and
tobacco smoking [15]. Recognised occupational factors include
benzene and its derivatives [16], while an excess of MDS is
reported in agricultural and industrial workers [15, 17]. Those
‘secondary MDS’, particularly cases occurring after chemother-
apy, generally have poor prognostic factors, including complex
cytogenetic findings involving chromosomes 5 and/or 7 and/or
17p, constituting the so-called alkylator type, therapy-associated
haematological malignancies.
diagnosis
Well-established and necessary diagnostic tools for MDS with
widespread availability are peripheral and differential blood
counts, cytomorphology of peripheral blood and bone marrow
smears and cytogenetics of bone marrow cells. At initial diagno-
sis, histology of bone marrow trephine biopsies is strongly
recommended, especially in the case of difficult diagnosis and
because of its potential prognostic information.
The medical history of the patient can provide important
information relating to differential diagnoses such as history of
medication or ingestion of alcohol or other drugs, as well as an ex-
clusion of other diseases including autoimmune disorders, renal
failure, malignancies, chronic infections or inflammations, aplastic
anaemia and paroxysmal nocturnal haemoglobinuria [18]. Beyond
the mere diagnosis of MDS, one should classify every case accord-
ing to the World Health Organisation (WHO) criteria [19] and
should establish the prognosis by IPSS [7] and IPSS-R [8].
peripheral blood counts and differential
blood counts
Almost all patients with MDS have peripheral blood cytopaenias,
mostly anaemia with or without other cytopaenias. If blood
counts only modestly deviate from normal values, repeated
controls are recommended.†Approved by the ESMO Guidelines Working Group: June 2014.
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laboratory parameters
Important laboratory values supporting or excluding the diagno-
sis of MDS are lactate dehydrogenase (LDH), ferritin, transferrin
and transferrin saturation, reticulocyte counts, vitamin B12 and
folate concentrations, haptoglobin, endogenous erythropoietin
(EPO) and creatinine levels. They can serve to exclude the differ-
ential diagnoses of iron deficiency anaemia, haemolytic anaemia,
vitamin B12 or folate deficiency and renal anaemia. If MDS is
diagnosed, ferritin and LDH also have a certain prognostic value,
and the EPO level can support a decision for or against treatment
with erythropoiesis-stimulating agents (ESAs).
cytomorphology
The hallmarks of cytomorphology in MDS are the determin-
ation of dysplastic signs in erythropoiesis, granulopoiesis and
megakaryopoiesis in the bone marrow and/or peripheral blood
and the enumeration of blast cells again in the bone marrow
and/or peripheral blood. In the bone marrow, histology of
trephine biopsies is of great additional value.
In early MDS with only mild morphological abnormalities,
certain cases with persistent, unexplained cytopaenias are called
idiopathic cytopaenias of uncertain significance (ICUS). In
patients with dysplastic features in the bone marrow but no or
only very mild peripheral blood cytopaenias and a normal kar-
yotype, idiopathic dysplasia of unknown significance (IDUS)
[20] can be diagnosed if no other cause of dysplasia is apparent
(see Table 1). Of note, however, the terms ICUS and IDUS
(although they are consensus statements from a MDS working
conference) are not universally accepted and are not included in
the current 2008 WHO classification.
When evaluating MDS peripheral blood films and bone
marrow slides, a number of cytological abnormalities should be
taken into account; a list of those items is given in Table 2 [21].
For the diagnosis of MDS, the recommended number of cells that
should be reviewed per slide is 200 for the peripheral blood film
and up to 500 for the bone marrow [19]. The bone marrow blast
count is crucial in MDS, given its paramount prognostic value
and must be evaluated morphologically in marrow aspirates (less
so with other methods) according to WHO and International
Working Group (IWG) criteria. ‘Blasts’ should include agranular
blasts and myeloblasts, but not promyelocytes.
histopathology
In Europe, contrary to in the United States, MDS (like acute leu-
kaemias) are mainly diagnosed by bone marrow aspirate rather
than with a biopsy. Bone marrow trephine biopsy, however, is
very useful in the case of hypocellular aspirates or dry puncture,
where hypoplastic MDS or fibrotic MDS may be diagnosed. It
may also be important for other differential diagnoses. In expert
hands, histomorphology can provide additional information
on dysplastic features and prognostic information, especially
by showing fibrosis (see below). It is therefore strongly recom-
mended in addition to bone marrow aspiration.
cytogenetics
In MDS, clonal chromosome abnormalities can be observed in
30% to >80% of patients depending on the MDS subtype and
whether the disease is de novo or chemo- or radiotherapy-
Table 2. Signs of dysplasia in myelodysplastic syndromes
Peripheral blood
Granulocytes Pseudo-Pelger cells, abnormal chromatin
clumping, hypo-/degranulation, left shift
Platelets Giant platelets, anisometry of platelets
Red cells Anisocytosis, poikilocytosis, dimorphic
erythrocytes, polychromasia,
hypochromasia, megalocytes, basophilic
stippling, presence of nucleated
erythroid precursors, teardrop cells,
ovalocytes, fragmentocytes
Bone marrow
Cellularity of the
marrow
Typically hypercellularity, rarely
hypocellularity
Erythropoiesis Megaloblastoid changes, multi-nuclearity,
nuclear budding, nuclear bridges,
atypical mitoses, sideroblastosis, ring
sideroblasts, periodic Acid–Schiff-
positive red cell precursors
Megakaryopoiesis Micro-megakaryocytes, mononuclear
megakaryocytes, dumbbell-shaped
nuclei, hypersegmentation, multi-
nuclearity with multiple isolated nuclei
Granulocytopoiesis Left shift, increased medullary blast count,
Auer rods or Auer bodies, hypo-/
degranulation, Pseudo-Pelger cells,
nuclear anomalies (e.g.
hypersegmentation, abnormal
chromatin clumping), deficiency of
myeloperoxidase, increase and
morphological abnormality of
monocytes
Table 1. Definition of ICUS and IDUS [18]
Characteristics
ICUS Mild cytopaenias (haemoglobin <11.0 g/dl, neutropaenia
<1500/μl and/or thrombocytopaenia <100.000/μl and
lack of significant dysplasia in the bone marrow but
exclusion of other diseases and/or
no clonal cytogenetic/molecular markers
IDUS Mild cytopaenias for >6 months (hb ≥11/dl, neutrophils
≥1500/μl, platelets ≥100 000/μl, all below lower limit of
normal) or
no cytopaenias but marked dysplasia in >10% of cell
lineages and
no clonal cytogenetic/molecular markers
ICUS, idiopathic cytopaenias of uncertain significance; IDUS,
idiopathic dysplasia of unknown significance.
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induced [22]. In the remaining 20%–70% of patients with a
normal karyotype, there is growing evidence that sub-microscopic
alterations such as point mutations, micro-deletions, micro-
amplifications, epigenetic changes or copy-number neutral loss of
genetic information as by uniparental disomy provide the genetic
basis for the disease [2, 23, 24]. Karyotype also has the highest
prognostic weight of all parameters in the IPSS-R [8].
Chromosome banding analysis is carried out on dividing
metaphase cells. Generally, whenever possible, 20–25 meta-
phases should be structurally analysed not to miss smaller cell
clones which are quite frequent, especially in low-risk MDS.
According to the International System for Human Cytogenetic
Nomenclature (ISCN), an abnormal clone is defined by at least
two metaphases with the same supernumerary chromosome or
structural change, or at least three metaphases with loss of the
same chromosome. Complex abnormalities are defined as three
or more independent abnormalities in at least two metaphases.
An adequate cytogenetic report should contain a correct
formula describing the karyotype according to the most recent
ISCN criteria [25]. Cytogenetic analysis should follow minimal
standards fixed by the ‘Workpackage Cytogenetics’ of the
European Leukaemia Net (Figure 1). These relate to cell cultur-
ing, analytical expenditure and the use of additional fluores-
cence in situ hybridisation analyses [26].
In an international database of 2124 MDS patients, 52% of
patients had one or more clonal cytogenetic abnormality by
chromosome banding. Abnormal karyotypes showed a clear as-
sociation with the severity of MDS, increasing with the medul-
lary blast count and the intensity of cellular dysplasias [22].
Several independent studies have proven the dismal outcome
related to complex abnormalities, especially in the presence of
monosomies (monosomal karyotype); however, there is a growing
body of evidence that it is not the monosomies per se but rather
the complexity of chromosomal changes that determines the
dismal outcome [22, 27–30].
additional diagnostic tests
When MDS is uncertain, especially in cases of ICUS or IDUS
with normal karyotype, analysis of somatic mutations and flow
cytometry analysis of marrow cells could be useful to ascertain
diagnosis. Acquired mutations, especially in genes involved
in epigenetic regulation and chromatin remodelling (TET2,
DNMT3A, ASXL1, IDH1/2, EZH2), pre-mRNA splicing factors
(SF3B1, SRSF2, U2AF1) transcription [TP53, RUNX1, (II) (III)]
and signalling transduction (e.g. NRAS, CBL) are seen in most
MDS, and can demonstrate clonal disease [31, 32] (Table 3),
while some flow cytometry abnormalities of myeloid precursors
Cytogenetics: At least 2 different cell cultures (24 h and 48 h)
(if 4 cultures were established additional 24 h and 72 h cultures are
recommendable)
Analysis of at least 10 (–20) metaphases (if abnormal),
or 20 (–25) if a normal karyotype is diagnosed
Normal karyotype or
insufficient number of
metaphases
Abnormal karyotype
FISH
Optional:
for all subtypes:
Probes for  5q31, cen7, 7q31, cen8,
TP53, 20q, cenY
Documentation and reporting
according to ISCN
Figure 1. Recommended standard algorithm for cytogenetic analysis in myelodysplastic syndromes [26]. FISH, fluorescence in situ hybridisation.
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are highly suggestive of MDS, although both procedures are still
used only in a minority of centres [33].
classification
A WHO classification of MDS, published in 2001 [19] and
updated in 2008 (Table 4) [34], divides MDS with <5% blasts
into those with either unilineage or multi-lineage dysplasia.
Within the subgroup of MDS with unilineage dysplasia, patients
with ring sideroblasts (pure sideroblastic anaemia) have a very
low AML progression rate and an excellent overall survival
(OS). Refractory anaemia with excess blasts (RAEB) patients
were sub-divided in RAEB-1 and RAEB-2, i.e. patients with
5%–9% blasts and patients with 10%–19% blasts (20% and more
blasts are now considered to be AML patients). While all of
these subgroups can be defined solely on a morphological basis,
the entity of del(5q) MDS is not defined by morphological
criteria, but by the occurrence of isolated del(5q), making cyto-
genetic analysis mandatory (see above). Finally, chronic myelo-
monocytic leukaemia was excluded and was moved to the
subgroup of myelodysplastic/myeloproliferative neoplasms.
prognosis and risk assessment
The natural course of MDS is highly variable, with survival
ranging from a few weeks to several years [35]. The median OS
is 15–30 months and the risk of progression to AML is 25%–
35% at 5 years [36]. Bone marrow failure (infection and haem-
orrhage) is the leading cause of death, with more patients dying
before overt AML has occurred [36].
An individual risk-adapted treatment strategy is essential in
MDS. Specific cytogenetic abnormalities, percentage of marrow
blasts and number and severity of cytopaenias are the main prog-
nostic factors in MDS. The IPSS [7] and its recent revision (IPSS-
R, Table 5) [8] are based on these three variables. They have been
validated in external series [37], and their use is strongly
recommended for predicting outcome and planning treatment
[38]. The IPSS-R is used to stratify patients into five risk groups
(very low, low, intermediate, high and very high risk), with clear
differences in OS and risk of progression to AML [8]. Of note,
currently conventional IPSS remains the most widely used
system, and the system used by health agencies for drug approval
in MDS. For therapeutic purposes, IPSS low and intermediate-1
patients are generally grouped in ‘lower risk’ MDS, and inter-
mediate-2 and high-risk patients in ‘higher risk’MDS.
Patient-related characteristics such as age [8], Eastern
Cooperative Oncology Group (ECOG) performance status
[8] and comorbidities [39] are also relevant for establishing
prognosis and treatment choice, particularly in lower risk MDS.
Other disease-related factors include multi-lineage dysplasia
[40], red blood cell (RBC) transfusion dependence [40], serum
LDH, ferritin and β2-microglobulin [7] and bone marrow fibrosis
[39]. Finally, flow cytometry immunophenotyping [33] and gene
somatic mutation profiling (especially the most frequent, i.e. TET 2,
SF3B1, SRSF2, ASXL1, RUNX1, DNMT3a, EZH2, TP53 and
RAS, mutations) may also improve risk stratification [2, 31, 32],
but data on their independent prognostic impact are still lacking
to recommend use in routine practice. The prognostic impact of
combined mutations as well as combinations of gene mutations
with distinct karyotype abnormalities is also unclear at this time.
Finally, most prognostic factors in MDS have been established
independently of treatment, particularly in cohorts receiving
mostly supportive care. With the availability of treatments having
an impact on disease evolution, including alloSCT and hypo-
methylating agents (HMAs), factors that may be prognostic of
outcome in patients treated with these treatments are starting to be
defined.
response criteria in MDS
Response criteria to treatment, in MDS, are based on recom-
mendations of an IWG (most recently updated in 2006), that
define two types of responses. The first type considers responses
to treatments aimed at modifying the disease course (mainly
alloSCT, intensive chemotherapy and HMAs), and includes
complete remission (CR), partial remission (PR), stable disease
and progression. The second type evaluates improvement of
cytopaenias (‘haematological improvement’ or HI) in one, two
or three lineages (erythroid, platelet and neutrophil responses),
and is particularly adapted to treatments which, like growth
factors, can improve these cytopaenias, but with no obvious
effect on the disease course. While CR and PR are generally
associated with improvement in cytopaenias, the second type of
response is often designed as ‘stable disease with HI (on the
erythroid and/or platelet and/or neutrophil) lineage.’
treatment of IPSS INT-2 and high-risk
(higher risk) MDS patients
Although the division is schematic, it is customary since publi-
cation of the classical IPSS to separate MDS into ‘higher risk’
MDS (corresponding to IPSS high or intermediate-2) and ‘lower
risk’ (corresponding to IPSS low or intermediate-1). Higher risk
MDS carry a major risk of progression to AML and short
Table 3. Most frequent somatic mutations observed in MDS (other
mutations are seen in <5% of the cases)
Gene function Gene Mutation
frequency
Epigenetic regulators
and chromatin-
remodelling factors
TET 2 15%–25%
ASXL1 10%–20%
DNMT3a 10%
IDH1/2 5%–10%
Pre-mRNA splicing
factors
SF3B1 15%–30%
SRSF2 10%–15%
U2AF1 5%–10%
Transcription factors RUNX 1 10%–15%
TP 53 5%–10%
Signaling moleculesa N RAS/K RAS 10%
aIn this group, NPM1 mutations and FLT3 duplications are rare in
MDS, and suggest imminent progression to AML; JAK 2 mutations
are also rare, contrary to myeloproliferative neoplasms.
MDS, myelodysplastic syndrome; AML, acute myeloid leukaemia.
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survival, and treatment in those patients should aim, whenever
possible, to modify the natural disease course including alloSCT,
HMAs and, although now less often, chemotherapy (mainly in-
tensive anthracycline–AraC combinations) [41]. In most higher
risk MDS, HMAs are the first-line reference treatment.
hypomethylating agents
In patients with MDS IPSS INT2 high risk, without major co-
morbidities and not eligible for alloSCT, azacitidine is recom-
mended [I, A]. The use of azacitidine may be recommended
compared with the other HMA decitabine, because in a rando-
mised trial, azacitidine has been shown to be superior to con-
ventional care regimens (i.e. supportive care, low-dose AraC
and AML-like chemotherapy) [42, 43], whereas there was no
clear survival advantage with decitabine over conventional
treatment in two phase III trials.
Due to the fact that most patients respond only after several
courses, at least six courses of azacitidine are recommended,
with the following schedule: azacitidine 75 mg/m²/day s.c. for
7 days every 28 days [II, B] in order to properly evaluate its
efficacy. Alternative schedules (such as 5-day regimens), which
appear to give similar response rates as the classical 7-day
regimen in lower risk MDS, have not demonstrated their efficacy
in terms of survival advantage in higher risk MDS.
Besides induction of CR and PR, achievement of HI according
to IWG 2006 criteria, i.e. an improvement in cytopaenias
(mainly anaemia and/or thrombocytopaenia), should be consid-
ered indicative of response, because it has been shown to be
associated with a prolongation of survival [III, B] [44].
The use of azacitidine before HSC transplantation (HSCT)
appears promising and is currently being evaluated in clinical
trials.
Table 4. The WHO classification of myelodysplastic syndromes [34]
Disease Blood findings Bone marrow findings
Refractory cytopaenias with
unilineage dysplasia (RCUD)
Refractory anaemia (RA)
Refractory neutropaenia (RN)
Refractory thrombocytopaenia (RT)
Unicytopaenia or
bicytopaeniaa
No or rare blasts (<1%)b
Unilineage dysplasia: ≥10% of the cells in one myeloid lineage
<5% blasts
<15% of erythroid precursors are ring sideroblasts
Refractory anaemia with ring
sideroblasts (RARS)
Anaemia
No blasts
≥15% of erythroid precursors are ring sideroblasts
Erythroid dysplasia only
<5% blasts
Refractory cytopaenia with multi-
lineage dysplasia (RCMD)
Cytopaenia(s)
No or rare blasts (<1%)b
No Auer rods
<1 × 109/l monocytes
Dysplasia in ≥10% of cells in two or more myeloid lineages
<5% blasts in marrow
No Auer rods
±15% ring sideroblasts
Refractory anaemia with excess blasts-
1 (RAEB-1)
Cytopaenia(s)
<5% blastsb
No Auer rods
<1 × 109/l monocytes
Unilineage or multi-lineage dysplasia
5%–9% blastsb
No Auer rods
Refractory anaemia with excess blasts-
2 (RAEB-2)
Cytopaenia(s)
5%–19% blasts
Auer rods±c
<1 × 109/l monocytes
Unilineage or multi-lineage dysplasia
10%–19% blasts
Auer rods±c
Myelodysplastic syndrome:
unclassified (MDS-U)
Cytopaenias
≤1% blastsb
Unequivocal dysplasia in <10% of cells in one or more myeloid cell lines when
accompanied by a cytogenetic abnormality considered as presumptive evidence
for a diagnosis of MDSd
<5% blasts
MDS associated with isolated del(5q) Anaemia
Usually normal or
increased platelet count
No or rare blasts (<1%)
Normal to increased megakaryocytes with hypolobulated nuclei <5% blasts
No Auer rods
Isolated del(5q) cytogenetic abnormality
aBicytopaenia may occasionally be observed. Cases with pancytopaenia should be classified as MDS-U.
bIf the marrow myeloblast percentage is <5% but there are 2%–4% myeloblasts in the blood, the diagnostic classification is RAEB-1. Cases of RCUD
and RCMD with 1% myeloblasts in the blood should be classified as MDS-U.
cCases with Auer rods and <5% myeloblasts in the blood and <10% in the marrow should be classified as RAEB-2.
dUnbalanced abnormalities: −7 or del(7q), −5 or del(5q), i(17q) or t(17p), −13 or del(13q), del(11q), del(12p) or t(12p), del(9q), idic(X)(q13).
Balanced abnormalities: t(11;16)(q23;p13.3), t(3;21)(q26.2;q22.1), t(1;3)(p36.3;q21.2), inv(3)(q21q26.2), t(2;11)(p21;q23), t(6;9)(p23;q34).
Not considered as definitive evidence for MDS: +8, del(20q), –Y.
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AML-like chemotherapy
AML-like intensive chemotherapy has limited indication in
higher risk MDS patients. In particular, MDS patients with un-
favourable karyotype show few CRs and shorter CR duration
[45]. This treatment can be envisaged for younger patients (gen-
erally <60–65 years of age) with favourable cytogenetics accord-
ing to IPSS categories and marrow blasts >10%, preferably as a
bridge to alloSCT [I, B].
Suggested regimens with equivalent efficacy deduced from
retrospective analyses are combinations of cytarabine with idar-
ubicin, fludarabine or topotecan [IV, B] [41]. No improvement
of outcome was reported by the addition of granulocyte–macro-
phage colony-stimulating factor (GM-CSF) or granulocyte
colony-stimulating factor (G-CSF) [IV, C].
A direct comparison of the efficacy of AML-like chemother-
apy versus azacitidine has been carried out in a small number of
MDS patients and only in one randomised phase III trial: it sug-
gested a superiority of the HMA without reaching statistical
significance, but the number of patients was too small for any
conclusion. A retrospective comparison of AML-like chemo-
therapy versus decitabine was carried out [46] in two groups of
matched MDS patients and, while CR rates were equivalent,
survival advantage was obtained only with the use of an HMA.
low-dose chemotherapy
Low-dose cytarabine at the most prevalent schedules and dose
(AraC 20 mg/m2/day, 14–21 days/every 4 weeks) was found to
be significantly inferior to azacitidine (in terms of response and
survival) in a randomised phase III study [42], especially in
patients with unfavourable cytogenetics. However, low-dose
cytarabine may still be a treatment option in higher risk MDS
patients with normal karyotype [47] who are not candidates for
any intensive chemotherapy or alloSCT, in particular when ad-
ministration of azacitidine or decitabine is not possible (includ-
ing for economic reasons) [IV, C]. In these patients, CR and PR
are reached in 15%–20% of cases with significant myelosuppres-
sive effects [48, 49].
second-line treatment
IPSS higher risk MDS patients who fail to respond to azacitidine
or are primary refractory to HMAs have an extremely poor sur-
vival (median <6 months) except for patients potentially eligible
for alloSCT [50]. Retreatment with AML-like chemotherapy or
low-dose AraC yields dismal results. The recommended ap-
proach is to enrol such patients in a clinical trial with investiga-
tional agents and, if the patient has become eligible for alloSCT,
proceed to transplant [IV, B] [50].
allogeneic stem cell transplantation
At present, alloSCT is the only potentially curative treatment of
higher risk MDS patients [I, A]. The major obstacle to alloSCT is
the fact that most MDS patients are above the age of 70 years.
Co-morbidity, age, IPSS and IPSS-R score, cytogenetics, condi-
tioning regimen and donor selection are predictors of post-trans-
plant outcome [51, 52] and should be taken into account carefully
during the decision process. All patients diagnosed with higher
risk MDS aged <65–70 years (although particularly ‘fit’ patients
aged >70 years may sometimes be considered) should be evaluated
for alloSCT eligibility and human leukocyte antigen (HLA)-identi-
cal (or single antigen mismatched) siblings or matched unrelated
individuals should be considered as suitable donors [I, A] [52].
Regarding conditioning regimens, there is no randomised
trial comparing reduced-intensity conditioning (RIC) to mye-
loablative approaches. At present, relapse seems to be higher in
patients receiving RIC; therefore, patients aged <55 years and
without co-morbidities should probably be offered myeloabla-
tive HSCT [IV, C].
Alternative sources such as cord blood should be further eval-
uated in clinical trials [II, C] [52]. It is debated whether treat-
ment aimed at reducing the blast count should be carried out
before alloSCT with AML-like chemotherapy or HMAs. This is
Table 5. Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes [8]
Prognostic characteristics Points
0 0.5 1 1.5 2 3 4
Cytogenetic risk categorya Very good Good Intermediate Poor Very poor
Blasts in bone marrow, % ≤2 >2%–5% 5%–10% >10%
Haemoglobin, g/dl ≥10 8–<10 <8
Platelet count, ×109/l ≥100 50–<100 <50
Absolute neutrophil count, ×109/l ≥0.8 <0.8
IPSS-R risk group Score Median overall survival, years Median time to 25% AML evolution, years
Very low ≤1.5 8.8 NR
Low >1.5–3 5.3 9.4
Intermediate >3–4.5 3.0 2.5
High >4.5–6 1.6 1.7
Very high > 6 0.8 0.7
aVery good: –Y and del(11q) as single abnormalities; good: normal, del(5q), del(12p) and del(20q) as single abnormalities, double abnormalities
including del(5q); intermediate: del(7q), +8, +19, i(17q) and any other single abnormalities, any other double abnormalities; poor: −7 and inv(3)/t(3q)/
del(3q) as single abnormalities, double abnormalities including −7/del(7q), complex (3 abnormalities); very poor; >3 abnormalities.
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generally considered when marrow blasts are >10%, especially
for non-myeloablative alloSCT.
treatment of lower risk MDS
In lower risk MDS, the risk of AML progression is smaller and
survival longer than in higher risk MDS, with about one-half of
elderly patients dying from causes other than the consequences of
MDS or AML [53]. In lower risk MDS, the main priority is gener-
ally the treatment of cytopaenias, mainly of anaemia (usually the
predominant cytopaenia), and the improvement in quality of life
(QoL). Still, some of these patients may be identified as carrying
poorer prognosis, either rapidly by their revised IPSS score [8] or
by other biological characteristics [54, 55], or subsequently by
their resistance to first-line treatment [56], and may benefit from
treatments generally applied to higher risk MDS.
Anaemia, because of failure of specific treatments, often even-
tually requires repeated RBC transfusions, leading to potential
iron overload [42].
treatment of anaemia
RBC transfusions or drugs?
Chronic RBC transfusions could be considered as the sole
approved treatment of anaemia of lower risk MDS, as very few
drugs are approved in this situation and none has been demon-
strated to improve survival. However, chronic RBC transfusions
are associated with chronic anaemia, leading to excess morbid-
ity, and they cannot completely correct impaired QoL [57, 58].
Although this remains disputed (see below), iron overload due
to RBC transfusions may also be deleterious to various organs
[57, 59]. Finally, researchers have found recently that, in lower
risk MDS with anaemia, receiving ESAs had no impact on pro-
gression to AML but was an independent, favourable prognostic
factor for survival [IV, B] [60–63].
first-line treatment of anaemia in lower risk MDS
*patients without del(5q): ESAs. ESAs, i.e. recombinant EPO or
darbepoetin (DAR), remain the first choice treatment of
anaemia in most lower risk MDS without del(5q) [60]. Weekly
doses of 30 000–80 000 units of EPO or 150–300 μg of DAR alfa
injection yield ∼60% of erythroid responses, according to IWG
2006 response criteria [64], when the baseline EPO level is low
and transfusion requirement is absent or limited, which is now
the case in most patients where this treatment is considered
[I, A] [60–62, 65, 66]. The efficacy of ESAs can be further
improved by the addition of G-CSF [67, 68], and there are no
data showing that one ESA is superior to another.
Responses to ESA occur within 8–12 weeks of treatment.
Median duration of response to ESA is ∼2 years, with longer
responses in patients with major response according to IWG
2000 criteria [64], IPSS low or intermediate-1, marrow blasts
<5% and no multi-lineage dysplasia [60–62].
*lower risk MDS with del 5q: lenalidomide. Anaemia of lower
risk MDS with del 5q, compared with that of other lower risk MDS,
shows lower response rates and significantly shorter responses to
ESA [69]. However after ESA failure, it responds to lenalidomide
(LEN) in 60%–65% of the subjects, with a median duration of RBC
transfusion independence (RBC-TI) of 2–2.5 years [I, A] [70, 71].
The recommended initial dose is 10 mg/day, 3 weeks out of every 4
weeks [71]. Cytogenetic response (CyR) is achieved in 50%–75% of
subjects (including 30%–45% complete CyR). TP53 gene
mutations, found in ∼20% of lower risk MDS with del 5q, seem to
confer resistance to LEN and a higher risk of AML progression
[72], and their presence may require more aggressive treatment.
Grade 3 or 4 neutropaenia and thrombocytopaenia, seen in ∼60%
of patients during the first weeks of treatment, constitute the most
common adverse events associated with LEN [70, 71]. Close
monitoring of blood counts is therefore required during this
period, with dose reduction and/or addition of G-CSF if required.
second-line treatments for anaemia of lower risk
MDS
*patients without del 5q. Treatment after ESA failure (primary
resistance or relapse after a response) in patients who remain
with IPSS low or intermediate-1 MDS is still disappointing
overall, with most patients eventually requiring long-term RBC
transfusions. Second-line treatments currently used include
anti-thymocyte globulin (ATG), HMAs and LEN.
Immunosuppressive drugs, including anti-lymphocyte or ATG,
with or without ciclosporin, can yield an erythroid response (asso-
ciated with response of other cytopaenias, especially thrombocyto-
paenia), in 25%–40% of the patients treated [73–77]. ATG results
are better in relatively young (<65 years) low-risk MDS patients
with a RBC transfusion history of <2 years, with normal karyotype
(or possibly trisomy 8), with no excess blasts, HLA DR15 geno-
type, and possibly in patients with thrombocytopaenia in addition
to anaemia, a small paroxysmal nocturnal haemoglobinuria clone
or with marrow hypocellularity [III, B] [73]. Therefore, this treat-
ment is generally proposed to a relatively small minority of
patients. HMAs have been reported to yield RBC-TI in 30%–40%
of the patients [78, 79], and may also be effective on other cytopae-
nias in lower risk MDS [III, B]. They are approved in this situation
in several countries, including the United States.
LEN yields RBC-TI in 25%–30% of lower risk MDS without
del 5q resistant to ESA [80, 81], and the combination of LEN
and ESA may yield higher RBC-TI rates than LEN alone in
patients resistant to an ESA alone [I, B] [82].
*patients with del 5q. Resistance to LEN in lower risk MDS
with del 5q is associated with poor prognosis, even if no
immediate progression to high-risk MDS is observed. Patients
with TP53 gene mutation may have a particularly poor outcome
[72]. Although no prospective data exist, these patients are likely
to be suitable candidates for approaches having demonstrated
a survival benefit in MDS, including HMAs and, whenever
possible, alloSCT [IV, B] [82].
treatment of neutropaenia
and thrombocytopaenia
In lower risk MDS, neutropaenia and thrombocytopaenia are
less frequent than anaemia, and are infrequently isolated or
profound.
White blood cells are <1.500 mm3 in only 7% of lower risk
MDS [83], and neutropaenia is rarely associated with life
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threatening infection if no drugs worsening neutropaenia are
used. G-CSF and GM-CSF can improve neutropaenia in 60%–
75% of these cases, and can be considered in the treatment of
neutropaenic fever in addition to anti-infective drugs, but their
prolonged use has not had a demonstrated impact on survival.
Platelets <50 000/mm3 are seen in ∼30% of low-risk MDS [83].
High-dose androgens can improve thrombocytopaenia in about
one-third of thrombocytopaenic lower risk MDS, but response is
generally transient [III, C] [84–86]. The thrombopoietic (TPO)
receptor-agonist romiplostim at high dose (500–1.500 μg/week)
yielded 55% platelet responses in a phase II trial in lower risk
MDS with thrombocytopaenia. However, in ∼15% of the patients,
a transient rise in marrow blasts was seen, which was reversible
after drug discontinuation. In a randomised phase II study versus
placebo in lower risk MDS with thrombocytopaenia, romiplostim
significantly reduced the incidence of severe bleeding and platelet
transfusions [87]. While there was a suspected increase in the
AML risk upon first analysis, this was not confirmed by later
follow-up [87]. Eltrombopag, the other available TPO receptor
agonist, is also currently being tested in both lower risk
and higher risk MDS. Lower risk MDS patients seem to be par-
ticularly responsive to treatment with eltrombopag [88].
ATG and HMAs appear to give platelet response in 35%–40%
of the cases of lower risk MDS, in addition to erythroid
responses [III, C] [74, 77, 89]. See Figures 2 and 3.
supportive care and chelation therapy
in MDS
Supportive care is required in all patients with MDS at some
point of the disease, and may be the only treatment of some
patients in the long term, especially those with transfusion-
dependent anaemia not responding to any of the agents
described above [90]. In patients requiring repeated RBC
transfusions, it is recommended to administer transfusions at
sufficiently high haemoglobin threshold, i.e. at least 8 g/dl, and
9 g/dl or even 10 g/dl in case of co-morbidities worsened by
anaemia or in case of poor functional tolerance and/or poor
QoL or in elderly persons who are still very active. A sufficient
number of RBC concentrates should be transfused each time,
if necessary over 2 or 3 days, to increase the haemoglobin
level >10 g/dl, and thereby limit the effects of chronic anaemia,
especially on QoL [IV, A].
Except in patients receiving myelosuppressive drugs, prophy-
lactic platelet transfusions are less used than RBC transfusions
in MDS, especially in the long term. Likewise, prophylactic anti-
biotics and/or G-CSF are not recommended in case of neutro-
paenia, as they have not shown any impact on survival, but
rapid onset of broad spectrum antibiotics is mandatory in these
patients in case of fever or symptoms of infection. Short-term
use of G-CSF during severe infections could be useful in neu-
tropaenic patients, but this indication has not been validated.
Psychosocial support and contacts with patient support groups
(when they exist) should be systematically offered.
A large debate exists about the deleterious effect of iron over-
load in MDS patients and whether iron chelation may be useful
in patients with iron overload. In particular, while heart iron
overload is a well-documented cause of heart failure in children
with thalassaemia [91, 92], its incidence and clinical conse-
quences are less certain in MDS patients receiving transfusions,
particularly as many already have other causes of cardiac morbid-
ity [40, 93]. However, heart MRI studies show that heart iron
overload (reflected by a decrease in MRI heart T2*) is frequent in
patients having received at least 70–80 RBC concentrates or more,
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Frail patients
Age <60–65
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Allogeneic SCT
(preceded or not by CT or
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AML-like
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azacitadine
Azacitidine (at least 6
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In case of failure or
relapse, consider clinical
trials or symptomatic
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Supportive care
(RBC transfusions,
antibiotics...)
Higher-risk MDS
(IPSS high and int 2)
Figure 2. Treatment algorithm for higher risk myelodysplastic syndromes.
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a frequent situation in low-risk MDS, and that a heart T2* value
<20 ms is associated with decreased left ventricular ejection frac-
tion and a risk of heart failure [94]. It has been suggested in retro-
spective studies that adequate chelation in highly transfused
patients may improve their survival [IV, C] [95–97]. Prospective
randomised studies are underway to confirm those results.
In the absence of prospective studies, published recommenda-
tions for iron chelation therapy so far only result from expert
opinions [V] [98], which generally advocate starting chelation
in patients with relatively favourable prognosis (i.e. low or in-
termediate-1-risk MDS), who have received 20–60 RBC con-
centrates, or if serum ferritin raises above 1000–2500 U/l, or if
cardiac T2* is significantly reduced. Future candidates to alloSCT
should be chelated early. Indeed, although the underlying
mechanisms are unclear, it appears that even relatively moderate
iron overload before alloSCT is associated with increased trans-
plant-related mortality [II, B] [99–101].
Iron chelation is now made easier by the availability of oral
iron chelators (especially deferasirox), in addition to the classical
parenteral deferoxamine. Deferasirox is however frequently
associated with gastrointestinal side-effects, and cannot be used
in patients with renal failure [102]. Deferiprone, another oral
iron chelator, is currently not approved for MDS in most coun-
tries, and can cause neutropaenia in a small percentage of
patients, a side-effect that is problematic in MDS [103].
personalised medicine
While many prognostic factors have been established in MDS,
as seen above, most of them have been defined irrespective of
treatment, in patient cohorts that mainly received supportive
care, and it is often unclear if they are predictive of the efficacy
of a given treatment. Furthermore, in spite of recent improve-
ments, there are still too few effective treatment options in MDS,
and there is limited choice for most patients.
The classical IPSS offers a valuable patient stratification, and
this is why it served as a basis in Figures 2 and 3 summarising
treatment indications: e.g. anaemia of IPSS low and intermedi-
ate-1 MDS often responds to ESAs, except in case of del 5q,
where LEN is very efficacious. On the other hand, in IPSS inter-
mediate-2 and high-risk patients, while azacitidine has shown it
could improve survival, there are currently limited other options
(except alloSCT, possible in a minority of patients).
Given the usual age of MDS patients, considering the patient’s
age, general condition and co-morbidities is also crucial before
making any treatment decisions.
patient follow-up
Except for follow-up of specific treatments, follow-up of MDS is
largely based on regular blood counts, to detect anaemia that
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approved or in
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EPO +/– G-CSF (low
success rate)
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Second-line
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Figure 3. Treatment algorithm for lower risk myelodysplastic syndromes.
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will require RBC transfusions, while severe thrombocytopaenia
may require platelet transfusions and severe neutropaenia man-
dates preventive measures against infection (e.g. during invasive
procedures), or, more importantly, rapid onset of broad spec-
trum antibiotics in case of fever or symptoms of infection.
Bone marrow examination, with or without karyotype, is
generally triggered by worsening of cytopaenias or appearance of
circulating blasts rather than systematically carried out at regular
intervals.
note
Levels of evidence and grades of recommendation have been
applied using the system shown in Table 6. Statements without
grading were considered justified standard clinical practice by
the experts and the ESMO faculty.
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